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Background: Malignant pleural mesothelioma is a rare, invasive and often fatal neoplasm that develops
in the thin layer of tissue surrounding the lungs known as the pleura. Although rare, mesotheliomas do
occur in the young; their characteristics are distinct from those of older patients.
Case presentation: This is a case report of a 17-year-old boy who had moderate dyspnea, cough, right-
sided pleuritic chest pain, fever, headache and no weight loss. Physical examination showed a right
pleural effusion and chest roentgenograms revealed a homogenous opacity on lower right hemithorax.
Biochemical analysis of pleural ﬂuid showed hemorrhagic/turbid effusion compatible with exudate. It
was initially treated as an empyema. The pleural ﬂuid culture was negative. Adenosine deaminase level
was 34.3 U/L (admission) and 19.02 U/L (two weeks after). Pleural ﬂuid smear and culture for Mtb were
negative. During the open pleural biopsy, thickened pleura and multiple pale yellow nodules in the lung
were observed. The histopathological report was compatible with malignant pleural mesothelioma. With
this diagnosis, a chemotherapy regimen with cisplatin was initiated. After two cycles, the patient had no
clinical and radiological improvement. The patient is currently under regular follow up.
Conclusion: MPM is rare in young adults and its clinical presentation makes it different from mesothe-
lioma in elderly patients, so it will be necessary to identify the new risk factors that can identify these
patients.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Background
Malignant pleural mesothelioma (MPM) is a rare, aggressive and
hard-to-treat malignant neoplasm that commonly develops in
pleura and peritoneum [1]. Approximately 80% of MPM patients
have a history of exposure to asbestos [2]. However, it can take
decades to develop and, as a result, is usually thought of as a disease
of middle age and elder people [2]. Patients with MPM frequently
develop thoracic pain, dyspnea, weight loss and pleural effusion [3].
Unusual presentations have also been reported, though rarely [4,5].
Although rare, pleural mesothelioma does occur in the young; their
characteristics are different from those of older patients [6]. We
report a case of a teenager who had a large malignant pleuralPerez-Guzman), barrerarr@
odríguez), portilla.javier48@
Ltd. This is an open access article ueffusion.
2. Case presentation
A 17-year old male patient was admitted to our hospital on June
2015. He had smoked tobacco and marijuana cigarettes for three
months the previous year, as well as moderate alcohol consump-
tion. The patient was diagnosed with allergic rhinitis and bronchial
hyperreactivity at the age of 12 years old without regular treat-
ment. At hospital admission, he had 7 days with ﬁxed moderate
dyspnea, fever, right-sided pleuritic chest pain, headache, cough
and no weight loss. Physical examination revealed a pleural effu-
sion syndrome on the same side. No other associated clinical
ﬁnding was described. Chest x-ray showed a homogenous opacity
in lower right hemithorax (Fig. 1). A chest tube was inserted and
1600 ml of hemorrhagic/turbid pleural ﬂuid was drained. After we
diagnosed complicated parapneumonic pleural effusion, Clinda-
mycin and ceftriaxone were given. Several biochemical and
microbiological analyzes were performed.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. Chest X-ray demonstrated total lung reexpansion after thoracic tube insertion.
Mild pleural thickness is observed.
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pain only at the chest-tube insertion site. A second chest X-ray
showed a fully re-expanded left lung (Fig. 2). For the next 7 day at
least 750 ml daily of clear pleural ﬂuid was drained. Biochemical
analysis of pleural ﬂuid demonstrated an exudate with very low
glucose level 0.20 mg/dl. Pleural ﬂuid cultures were negative.
Because of the increase of pleural ﬂuid drainage up to 800 ml daily,
we decided to perform a closed pleural biopsy, which reported
negative results for tuberculosis and malignancy.
At admission, the adenosine deaminase (ADA) level was 34.3 U/L
in two weeks it decreased to 19.02 U/L. Acid-fast bacilli (AFB) for
pleural ﬂuid was negative, and culture for Mtb remained negative.
In spite of antibiotics, pleural ﬂuid drainage did not decrease
after 3 weeks, thus we decided to begin the anti-TB treatment.
However, after another week, no decrease in pleural ﬂuid drainage
was observed. Therefore, we decided to perform an open pleural
biopsy. During surgery, pleural thickening and multiple pale yellow
nodules in the lung were seen. After a diagnosis of malignancy,
pleurodesis was done twice with povidone-iodine but no decrease
in pleural ﬂuid drainage was obtained.
Unfortunately, the patient did not receive other treatment such
as pemetrexed, gemcitabine because theywere not available at that
moment, and extrapleurectomy is not a common surgical proce-
dure in our media.
Immunohistochemistry revealed tumor cells to be immunore-
active for calretinin (clone Z11-E3, Dako) cytokeratin 7 (BC-1, BIO-
CARE MEDICAL) and negative for WT1 (BC.6FeH2, BIOCARE
MEDICAL) NAPSIN A (TMU-Ad 02, BIOCARE MEDICAL). Based on
these ﬁndings; the cause of pleural effusionwas diagnosed asMPM.
With this diagnosis, a chemotherapy regimen with cisplatin was
initiated [7]. After two cycles, there was no clinical and radiological
improvement. The patient is currently under regular follow up.3. Discussion
The worldwide MPM incidence has been rising since the mid
20th century [8,9]. MPM is often considered a disease of the elderly
with a median age of 74 years [10]. However, there is a subgroup of
patients who are young [6]. Here, we showed the case of a teenager
withmassive pleural effusion, diagnosed withMPM and a review of
the literature. As far as we know, this is one of the few younger
patients with MPM reported until now.Fig. 1. Initial Chest X-ray demonstrated a large right pleural effusion, that occupies 2/3
parties of the right hemithorax accompanied with fever and right chest pain.To date, numerous epidemiological reports describe the elderly
population with MPM but outside of case studies [11,12], and small
cohorts [13,14] a detailed examination of young patients with MPM
has been less studied. An important ﬁnding of these reports is that
almost 15% of cases with MPM were younger than the age 40
[14e17]. In addition, other case-series have also found a lower
frequency for patients with MPM under 40 years old: i.e. Kane et al.
found ten of 172 cases (5.8%) [18], whereas Jones and Thomas in a
reviewof 5778 death certiﬁcates reported 298 cases (5.2%) between
the ages of 15 and 44 at the time of death [19]. The Surveillance,
Epidemiology, and End Results (SEER) database for mesothelioma
cases from 1990 to 2010 showed that about 2% (207) of the 12,345
mesothelioma cases studied occurred in people under 40 years old
[20].
Malignant mesothelioma (MM) in young people acts very
differently than it does in the older population. Thus, while almost
80% of the older MPM patients aremen, the disease is about equally
split between men and women in the younger age group [21].
Another difference between younger and older mesothelioma pa-
tients is the frequency of pleural and peritoneal mesothelioma. The
two types of mesothelioma are about evenly distributed in the
younger patients while 90% of older patients have the pleural va-
riety [21]. The younger group is also more likely to undergo cancer-
directly to surgery and to live longer afterward, even if they have a
type of mesothelioma that is usually considered less survivable
[22,23].
Most of the elderly patients diagnosedwithmesothelioma die of
the disease within a year of diagnosis. Improved overall survival of
the young mesothelioma patients with both pleural and peritoneal
mesothelioma indicates that mesothelioma in the young may
possibly have a different natural history and indeed be biologically
different from mesothelioma in elderly patients. Genomic and
expression studies of tumor samples from young and old patients
with mesothelioma will clarify the biological differences between
the two cohorts. To our knowledge, no such studies have been
conducted to date.
The relationship between MM and asbestos exposure it is well-
known. The latency period of MM is highly variable and can be as
short as 13 years or as long as 70, between exposure and diagnosis
[24]. Because of this long time span, most of those who are diag-
nosedwithMPM and other asbestos-related disease are in their 60s
or 70s.
MPM in young patients with occupational and non-occupational
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[12,18,25], and small population cohorts [26]. For instance,
considering the long latency period, MPM in the young boys is less
likely due to occupational exposure to asbestos ﬁbers [24]. Inter-
estingly, in a cohort of adults that had lived in an blue asbestos
mining town during their childhood, Reid et al. found lower mor-
tality rates among individuals exposed to asbestos when they were
15 years old and younger compared to adults with similar expo-
sures who were ﬁrst exposed when they were 15 years old or older
[26].
Occasionally, MPM is seen in young patients with no exposure
history. Brenner et al. described in 1981 seven cases 17 years old
with non-asbestos related mesothelioma, six of them had pleural
involvement, from these, one survived after surgery and chemo-
therapy after 5 years of follow-up [27]. Thus, in young MPM pa-
tients it is likely that increased genetic predisposition and/or
environmental exposure to carcinogenic mineral ﬁbers from an
early age are possible etiological factors in these patients [28]. A
genetic component in the etiology of the disease might in part
explain the relative rarity of MPM in young people. Recent studies
have identiﬁed germline mutations in the gene encoding BRCA1
associated protein-1 (BAP1) which can predispose to MPM [29,30].
Mesothelioma occurring in germline BAP1 mutation carriers have
been reported to be less aggressive clinically and associated with
prolonged survival compared with sporadic MPM [31]. In addition,
germline BAP1 mutations confer increased susceptibility for the
development of several other tumors including uveal melanoma,
cutaneous melanoma, renal cell cancers and possibly other cancers
[32].
Because our patient does not have a report of familiar clustering
of cancer, germline BAP1 mutations alone cannot explain the
development of MPM. Other candidate gene-based association
studies have also identiﬁed other genes that may play an additional
role in the development of this neoplasm [33]. Further research is
needed to better understand how genetic susceptibility or other
risk factors interact to cause mesothelioma in certain younger
people.
Younger patients with rare cancers such as those with meso-
thelioma require multidisciplinary care and are more likely to be
referred to large international cooperative groups to facilitate the
study of these infrequent tumors and develop registries, bio-
specimen banks, and clinical trials for these diseases [34]. Active
participation in these organizations could potentially offer invalu-
able informationwith regards to the incidence and numbers of new
patients with childhood mesothelioma and could, therefore, facil-
itate the planning of epidemiologic, biologic, and therapeutic trials
for this patient population.
4. Conclusion
This case is reported because malignant pleural mesotheliomas
are a rare cause of pleural effusion in the clinical practice among
younger adults. Additionally, the clinical presentation of MPM in
young adults is different from MPM in elderly patients. We believe
that this case together with all those reported in the literature
suggests that mesotheliomas of young people are a different
neoplasm entity from elderly patients and should be treated
differently. Likewise, further clinical and epidemiological studies
will be necessary to identify the new risk factors in these patients.
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